At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 31 enrolled
Drug / intervention
Brivanib Alaninate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)
In Brief
A Phase 2 clinical trial evaluating Brivanib Alaninate and Laboratory Biomarker Analysis for Cervical Adenocarcinoma and 4 related conditions. Completed, enrolled 31 participants across 43 sites.
Detailed Summary
This phase II trial studies how well brivanib alaninate works in treating patients with cervical cancer that has come back. Brivanib alaninate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Persistent Disease, Recurrent Cervical Carcinoma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2010
Enrollment StartApr 2011
Primary CompletionFeb 2014
TodayJul 2026
First PostedDec 28, 2010
Enrollment StartApr 4, 2011
Primary CompletionFeb 28, 2014
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 15.5 years ago
Interventions
Brivanib Alaninatedrug
Given PO
Laboratory Biomarker Analysisother
Correlative studies